BioSpace News Archive

LAIX Inc. announced its unaudited financial results for the second quarter ended June 30, 2019.

Lannett Company, Inc. announced that it has entered into a three-year advisory services agreement with its strategic alliance partner, Cediprof, Inc., a wholly owned subsidiary of privately held Neolpharma Group.

AMN Healthcare, the leader and innovator in healthcare workforce solutions and staffing services, has named Christine Mackey-Ross as Lead Executive Partner of Phillips DiPisa, an AMN Healthcare company.

REGENXBIO Inc. announced that an interim trial update from the RGX-314 Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration will be reported during a presentation at the Retina Subspecialty Day program of the American Academy of Ophthalmology 2019 Annual Meeting in San Francisco, CA.

Antibe Therapeutics Inc. provides an update on the Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346.

STAAR Surgical Company is announcing that the FDA in a letter dated August 23, 2019, stated that it has determined that STAAR has provided sufficient data to support initiation of a human clinical study in the United States of the EVO/EVO+ VISIAN® Implantable Collamer® Lens for Myopia, and EVO/EVO+ VISIAN® Toric Implantable Collamer® Lens for Myopia with Astigmatism.

New Chilmark Research report examines recent progress in precision medicine, as well as IT challenges and emerging solutions to enable mainstream adoption

Turn-key solution for the sustainable advancement and growth of clinical research sites

EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced it has closed $30M in new funding to complete enrollment of its pivotal SOLVE CRT clinical trial and to prepare for commercialization of the WiSE Cardiac Resynchronization Therapy (CRT) System.

Medable Inc. announced the University of Pennsylvania School of Medicine has partnered with Medable to accelerate patient enrollment and increase patient retention in the Light Treatment Effectiveness study, which evaluates home versus office-based narrow band ultraviolet B phototherapy for the treatment of psoriasis.